Editas Medicine Stock Analysis
| EDIT Stock | USD 1.31 0.06 4.38% |
Editas Medicine is overvalued with Real Value of 1.26 and Target Price of 3.75. The main objective of Editas Medicine stock analysis is to determine its intrinsic value, which is an estimate of what Editas Medicine is worth, separate from its market price. There are two main types of Editas Medicine's stock analysis: fundamental analysis and technical analysis.
The Editas Medicine stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Editas Medicine is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, National Mourning Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. Editas Stock trading window is adjusted to America/New York timezone.
Editas |
Editas Stock Analysis Notes
About 66.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.81. Some equities with similar Price to Book (P/B) outperform the market in the long run. Editas Medicine recorded a loss per share of 2.88. The entity had not issued any dividends in recent years. Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts. Editas Medicine operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 264 people. To learn more about Editas Medicine call Gilmore MD at 617 401 9000 or check out https://www.editasmedicine.com.Editas Medicine Investment Alerts
| Editas Medicine is way too risky over 90 days horizon | |
| Editas Medicine may become a speculative penny stock | |
| Editas Medicine appears to be risky and price may revert if volatility continues | |
| Editas Medicine has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 32.31 M. Net Loss for the year was (237.09 M) with loss before overhead, payroll, taxes, and interest of (166.93 M). | |
| Editas Medicine currently holds about 452.56 M in cash with (210.28 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.59, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 66.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: AstraZeneca deepens China investment Editas loses CFO to Dyne |
Editas Medicine Upcoming and Recent Events
| 28th of February 2024 Upcoming Quarterly Report | View | |
| 3rd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Editas Largest EPS Surprises
Earnings surprises can significantly impact Editas Medicine's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-02-22 | 2022-12-31 | -0.8 | -0.88 | -0.08 | 10 | ||
2024-05-08 | 2024-03-31 | -0.66 | -0.76 | -0.1 | 15 | ||
2020-05-07 | 2020-03-31 | -0.79 | -0.69 | 0.1 | 12 |
Editas Stock Institutional Investors
Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Balyasny Asset Management Llc | 2024-12-31 | 1.3 M | Ubs Asset Mgmt Americas Inc | 2024-12-31 | 1.2 M | Ubs Group Ag | 2024-12-31 | 1.1 M | Jane Street Group Llc | 2024-12-31 | 1.1 M | Aqr Capital Management Llc | 2024-12-31 | 1.1 M | Monaco Asset Management | 2024-12-31 | 1.1 M | Citadel Advisors Llc | 2024-12-31 | 922 K | Woodline Partners Lp | 2024-12-31 | 838.4 K | Jpmorgan Chase & Co | 2024-12-31 | 787.6 K | Blackrock Inc | 2024-12-31 | 7.3 M | Vanguard Group Inc | 2024-12-31 | 6.8 M |
Editas Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 108.7 M.Editas Profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.69) | (0.73) | |
| Return On Capital Employed | (0.95) | (1.00) | |
| Return On Assets | (0.69) | (0.73) | |
| Return On Equity | (1.77) | (1.68) |
Management Efficiency
Editas Medicine has return on total asset (ROA) of (0.3552) % which means that it has lost $0.3552 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.981) %, meaning that it created substantial loss on money invested by shareholders. Editas Medicine's management efficiency ratios could be used to measure how well Editas Medicine manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.73 in 2025. Return On Capital Employed is likely to drop to -1 in 2025. Liabilities And Stockholders Equity is likely to gain to about 394.2 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 44.6 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.63 | 2.46 | |
| Tangible Book Value Per Share | 1.63 | 2.46 | |
| Enterprise Value Over EBITDA | (0.03) | (0.04) | |
| Price Book Value Ratio | 0.78 | 0.61 | |
| Enterprise Value Multiple | (0.03) | (0.04) | |
| Price Fair Value | 0.78 | 0.61 | |
| Enterprise Value | 8.1 M | 7.7 M |
The operational strategies employed by Editas Medicine management play a crucial role in its market positioning. Assessing these strategies alongside financial data helps us evaluate the stock's investment potential.
Technical Drivers
As of the 22nd of March, Editas Medicine shows the Downside Deviation of 8.08, coefficient of variation of 2459.14, and Mean Deviation of 6.56. Editas Medicine technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.Editas Medicine Price Movement Analysis
The output start index for this execution was twenty-three with a total number of output elements of thirty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Editas Medicine middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Editas Medicine. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
Editas Medicine Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Editas Medicine insiders, such as employees or executives, is commonly permitted as long as it does not rely on Editas Medicine's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Editas Medicine insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Editas Medicine Outstanding Bonds
Editas Medicine issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Editas Medicine uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Editas bonds can be classified according to their maturity, which is the date when Editas Medicine has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| US281020AN70 Corp BondUS281020AN70 | View | |
| EDISON INTL 4125 Corp BondUS281020AM97 | View | |
| EIX 5 Corp BondUS281020AT41 | View | |
| EIX 5375 Corp BondUS281020AS67 | View | |
| US281020AR84 Corp BondUS281020AR84 | View | |
| EIX 695 15 NOV 29 Corp BondUS281020AW79 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Editas Medicine Predictive Daily Indicators
Editas Medicine intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Editas Medicine stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Editas Medicine Forecast Models
Editas Medicine's time-series forecasting models are one of many Editas Medicine's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Editas Medicine's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Editas Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Editas Medicine prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Editas shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Editas Medicine. By using and applying Editas Stock analysis, traders can create a robust methodology for identifying Editas entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (7.34) | (7.70) | |
| Operating Profit Margin | (7.77) | (8.16) | |
| Net Loss | (7.34) | (7.70) | |
| Gross Profit Margin | (1.15) | (1.20) |
Current Editas Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Editas analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Editas analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 3.75 | Buy | 16 | Odds |
Most Editas analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Editas stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Editas Medicine, talking to its executives and customers, or listening to Editas conference calls.
Editas Stock Analysis Indicators
Editas Medicine stock analysis indicators help investors evaluate how Editas Medicine stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Editas Medicine shares will generate the highest return on investment. By understating and applying Editas Medicine stock analysis, traders can identify Editas Medicine position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 127.5 M | |
| Common Stock Shares Outstanding | 82.3 M | |
| Total Stockholder Equity | 134.3 M | |
| Property Plant And Equipment Net | 47.1 M | |
| Cash And Short Term Investments | 269.9 M | |
| Cash | 131.5 M | |
| Accounts Payable | 5.5 M | |
| Net Debt | -96.5 M | |
| 50 Day M A | 1.5011 | |
| Total Current Liabilities | 77.2 M | |
| Other Operating Expenses | 283.5 M | |
| Non Current Assets Total | 52.3 M | |
| Non Currrent Assets Other | 5.2 M | |
| Stock Based Compensation | 21.4 M |
Additional Tools for Editas Stock Analysis
When running Editas Medicine's price analysis, check to measure Editas Medicine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Editas Medicine is operating at the current time. Most of Editas Medicine's value examination focuses on studying past and present price action to predict the probability of Editas Medicine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Editas Medicine's price. Additionally, you may evaluate how the addition of Editas Medicine to your portfolios can decrease your overall portfolio volatility.